The House voted to extend the Pentagon’s psychedelic research program through 2033, then blocked a Right to Try expansion that would have let doctors administer Schedule I drugs to patients with life-threatening conditions. Also this week: signs the FDA may let Resilient Pharmaceuticals resubmit its MDMA application without new trials, two competing pilot program bills advancing in Massachusetts, and a Senate patent bill with implications for how long drugmakers can fence off a compound.
The post Psychedelic Policy Briefing: Week of July 27th, 2026 appeared first on Psychedelics Today.
